{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-090634","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2021-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.015784+00:00","generated_at":"2026-06-30T06:23:24.035308+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outlook Therapeutics names C. Russell Trenary III CEO; Lawrence Kenyon stays CFO","bullets":["C. Russell Trenary III appointed President & CEO effective July 6, 2021; replaces Lawrence Kenyon who remains CFO.","Base salary $600,000; target annual cash bonus of 70% of base salary.","Received initial grant of 4,000,000 options + performance grant of 1,000,000 options with milestone vesting.","Company on track for NORSE TWO top-line data Q3 2021; plans BLA submission for ONS-5010 in Q1 2022.","Trenary previously led InnFocus through acquisition by Santen; over 35 years in life sciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-090634","json":"https://secwatch.observer/filing/0001104659-21-090634.json","markdown":"https://secwatch.observer/filing/0001104659-21-090634.md","text":"https://secwatch.observer/filing/0001104659-21-090634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/0001104659-21-090634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/tm2121712d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T06:23:24.035308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fb87aac3b","claim":"Lawrence Kenyon resigned as Chief Financial Officer at Outlook Therapeutics, Inc..","evidence_excerpt":"Mr. Trenary replaces Lawrence Kenyon, who resigned as President and Chief Executive Officer of the Company concurrently with Mr. Trenary’s appointment.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/0001104659-21-090634-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e4a16b6af8","claim":"C. Russell Trenary III was appointed as President and Chief Executive Officer at Outlook Therapeutics, Inc..","evidence_excerpt":"On July 6, 2021, the Board of Directors (the “Board”) of Outlook Therapeutics, Inc. (the “Company”) appointed C. Russell Trenary III as President and Chief Executive Officer of the Company and as a director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/0001104659-21-090634-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}